Target intelligence / Profile preview

Increased epidermal turnover

Molecular classification
Other
01

Overview

Increased epidermal turnover refers to a process in which cells in the epidermis proliferate, migrate, differentiate, and are shed at an accelerated rate. Normally, keratinocytes originate from stem cells in the basal layer and travel through the epidermal layers, becoming corneocytes that are eventually sloughed off at the skin surface[2][3][4][8]. The whole process takes 28–40 days in healthy adults but can be accelerated in certain conditions, notably psoriasis, where cell proliferation is greatly increased and cells are shed prematurely before full keratinization[1][5][6][7][8]. Epidermal turnover is regulated by multiple signaling pathways including EGF, FGF, Wnt, Notch, Hedgehog, BMP/TGFβ, and integrins[1]. Increasing turnover can be therapeutically beneficial for some skin conditions, but excessive or uncontrolled acceleration can impair barrier function and cause or worsen dermatitis, inflammation, or infection[1][4][8].

Other names
Epidermal cell turnoverSkin cell turnoverEpidermal renewalSkin regenerationCellular turnoverDesquamation
02

Mechanism of action

Induction of keratinocyte proliferation Acceleration of differentiation and upward migration Enhanced desquamation (shedding) of corneocytes Modulation of cellular signals such as EGF, FGF, Wnt, Notch, BMP/TGFβ, integrins

03

Biological functions

Cell proliferationCell differentiationCell death (shedding/sloughing)Skin barrier maintenanceWound healing
04

Disease associations

Psoriasis (characterized by increased epidermal turnover)Skin aging (delayed turnover)Acne (modulated by turnover rate)HyperpigmentationWound healing disorders
05

Safety considerations

Excessive turnover may impair barrier function, increasing risk of irritation or infectionOver-stimulation may provoke inflammation or chronic skin conditions (e.g., psoriasis)Disruption of skin barrier, leading to sensitivityPotential for increased trans-epidermal water loss (TEWL)
06

Interacting drugs

Topical retinoids (e.g., tretinoin, adapalene, tazarotene)

4 more in the full profile.

07

Biomarkers

Ki-67 (proliferation marker in basal layer)Terminal differentiation markers (involucrin, filaggrin)Epidermal thickness (clinical/pathological indicator)

Beyond the preview

Go deeper on Increased epidermal turnover.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Increased epidermal turnover.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call